Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06699849 · ClinicalTrials.gov registry record · Phase 2
Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis
A Phase 2 study of Sickle Cell Disease Vaso-occlusive Crisis, sponsored by CSL Behring.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
- 14
- Study locations
NCT06699849 is a Phase 2 study of Sickle Cell Disease Vaso-occlusive Crisis that is actively recruiting participants, run by CSL Behring. The registered enrollment target is 70 participants. The trial reports 14 study locations across 8 states.
The verdict
NCT06699849, a Phase 2 study of Sickle Cell Disease Vaso-occlusive Crisis, is actively recruiting participants, sponsored by CSL Behring.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
- 14
- Study locations
Study Summary
This is a phase 2, randomized, multiple-dose, placebo-controlled study designed to evaluate the safety, efficacy, and pharmacokinetics (PK) of CSL889 (human hemopexin) when given intravenously (IV) to adults and adolescents with sickle cell disease (SCD) experiencing vaso-occlusive crises (VOC). The main objectives of the study are to evaluate the safety and tolerability of CSL889 in study participants, and to assess how CSL889 affects the time it takes for VOC to resolve in participants with SCD.
Conditions Studied
Interventions
- DRUG Placebo
- BIOLOGICAL CSL889
Study Locations (14)
New York
- Mount Sinai Medical Center - New York
- Jacobi Medical Center - The Bronx
- Albert Einstein College of Medicine - The Bronx
Other
- Hacettepe Universitesi - Ankara
- Istanbul Universitesi - Istanbul
- Özel Acibadem Adana Hastanesi - Seyhan
Florida
- Golisano Children's Hospital - Fort Myers
- The Foundation for Sickle Cell Disease - Hollywood
Ohio
- University of Cincinnati - Cincinnati
- The Ohio State University - Columbus
California
- University of California Irvine - Orange
Maryland
- University of Maryland - Baltimore
Michigan
- Henry Ford Health System - Detroit
Pennsylvania
- University of Pittsburgh - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2025-07-10 |
| Est. Completion | 2027-08-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06699849
The ClinicalTrials.gov registry entry for NCT06699849 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CSL Behring, which has 71 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Sickle Cell Disease Vaso-occlusive Crisis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06699849 reports 14 study locations spanning 8 distinct geographic areas - top geographies include New York, Other, Florida.
Frequently Asked Questions
What is clinical trial NCT06699849 about?
NCT06699849 is a clinical study titled "Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis". This is a phase 2, randomized, multiple-dose, placebo-controlled study designed to evaluate the safety, efficacy, and pharmacokinetics (PK) of CSL889 (human hemopexin) when given intravenously (IV) to adults and adolescents with sickle cell disease (SCD) experiencing vaso-occlusive crises (VOC). The...
What is the current status of trial NCT06699849?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2025-07-10. Estimated completion is 2027-08-07.
What conditions does trial NCT06699849 study?
This clinical trial studies the following conditions: Sickle Cell Disease Vaso-occlusive Crisis.
What interventions are being tested in trial NCT06699849?
The interventions under investigation include: Placebo (DRUG), CSL889 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06699849?
This trial is sponsored by CSL Behring, which has 71 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06699849 being conducted?
This trial has 14 study locations across California, Florida, Maryland, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.